BioCentury | Mar 3, 2020
Politics, Policy & Law

Pricing speed bump for COVID-19 funding; Trump administration sending mixed messages on pricing, funding

Controversy over demands from Senate Democrats for pricing assurances are holding up a bill that will provide billions of dollars to combat the COVID-19 outbreak. Senate Minority Leader Chuck Schumer (D-N.Y.) and Sen. Patrick Leahy...
BC Extra | Sep 17, 2019
Company News

Couple charged with stealing secrets to form Chinese, U.S. biotech companies

The Department of Justice has charged two scientists, Yu Zhou and Li Chen, with stealing trade secrets from Nationwide Children’s Hospital Research Institute and forming two companies based on the stolen IP. The accusation comes...
BioCentury | Sep 7, 2018
Strategy

Thinking beyond Bi

Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there...
BC Extra | Aug 16, 2018
Politics & Policy

Innovative drugs reformer Bi out amid China vaccines scandal

Thursday’s resignation of Jingquan Bi, party secretary of the State Administration of Market Supervision, means that China has lost a champion of innovative biopharma products; however, it remains to be seen whether his departure will...
BC Extra | Jul 14, 2018
Politics & Policy

Democrats report on Novartis, Cohen inquiry

While Novartis AG (NYSE:NVS; SIX:NOVN) has admitted to bidding Michael Cohen for access to the Trump administration, the parties' relationship may have been more extensive than the pharma disclosed to the public, according to an...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
BC Extra | Nov 13, 2017
Politics & Policy

Ex-Lilly president to be nominated as HHS secretary

President Donald Trump Monday announced on Twitter that he intends to nominate Alex Azar as HHS secretary, and that he expects Azar to tackle prescription drug prices. “He will be a star for better healthcare...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BioCentury | Mar 31, 2017
Politics, Policy & Law

Balancing act

Scott Gottlieb’s toughest political challenge before and after confirmation as FDA commissioner will not be from a hostile Congress, but rather from White House officials who believe the agency is an impediment to medical progress...
BC Extra | Dec 7, 2016
Clinical News

BCMA-targeting therapies in ASH spotlight

At the American Society of Hematology meeting in San Diego, presentations late Monday highlighted data from Phase I studies of two candidates targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17 ; CD269)...
Items per page:
1 - 10 of 206